These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11561773)

  • 1. The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy.
    Cheung KL; Evans AJ; Robertson JF
    Breast Cancer Res Treat; 2001 Jun; 67(3):273-8. PubMed ID: 11561773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers.
    Cheung KL; Robertson FR
    Minerva Chir; 2003 Jun; 58(3):297-303. PubMed ID: 12955047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.
    Robertson JF; Jaeger W; Syzmendera JJ; Selby C; Coleman R; Howell A; Winstanley J; Jonssen PE; Bombardieri E; Sainsbury JR; Gronberg H; Kumpulainen E; Blamey RW
    Eur J Cancer; 1999 Jan; 35(1):47-53. PubMed ID: 10211087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?
    Dixon AR; Jackson L; Chan SY; Badley RA; Blamey RW
    Br J Cancer; 1993 Jul; 68(1):181-5. PubMed ID: 8318411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour marker measurements in the diagnosis and monitoring of breast cancer.
    Cheung KL; Graves CR; Robertson JF
    Cancer Treat Rev; 2000 Apr; 26(2):91-102. PubMed ID: 10772967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC).
    Di Gioia D; Heinemann V; Nagel D; Untch M; Kahlert S; Bauerfeind I; Koehnke T; Stieber P
    Tumour Biol; 2011 Aug; 32(4):777-85. PubMed ID: 21553235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA 15.3: fact or fiction?
    Dixon AR; Jönrup I; Jackson L; Chan SY; Badley RA; Blamey RW
    Dis Markers; 1991; 9(3-4):167-74. PubMed ID: 1813208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective measurement of therapeutic response in breast cancer using tumour markers.
    Robertson JF; Pearson D; Price MR; Selby C; Blamey RW; Howell A
    Br J Cancer; 1991 Oct; 64(4):757-63. PubMed ID: 1911226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer.
    Cheung KL; Pinder SE; Paish C; Sadozye AH; Chan SY; Evans AJ; Blamey RW; Robertson JF
    Int J Biol Markers; 2000; 15(3):203-9. PubMed ID: 11012094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers of breast cancer].
    Sławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2004 Jul; 58():292-300. PubMed ID: 15280799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data.
    Sölétormos G; Hyltoft Petersen P; Dombernowsky P
    Clin Chem; 2000 Jul; 46(7):939-49. PubMed ID: 10894837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
    Murray A; Clinton O; Earl H; Price M; Moore A
    Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
    Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
    Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3.
    Dixon AR; Price MR; Hand CW; Sibley PE; Selby C; Blamey RW
    Br J Cancer; 1993 Nov; 68(5):947-9. PubMed ID: 8217608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of metastatic breast cancer: distribution and radiological assessment at presentation.
    Whitlock JP; Evans AJ; Jackson L; Chan SY; Robertson JF
    Clin Oncol (R Coll Radiol); 2001; 13(3):181-6. PubMed ID: 11527292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
    Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features.
    James JJ; Evans AJ; Pinder SE; Gutteridge E; Cheung KL; Chan S; Robertson JF
    Br J Cancer; 2003 Aug; 89(4):660-5. PubMed ID: 12915874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.